Biologics Archives - CuraTeQ Biologics https://curateqbio.com/tag/biologics/ Mon, 22 Jan 2024 10:28:08 +0000 en-US hourly 1 https://wordpress.org/?v=6.9 https://static.curateqbio.com/wp-content/uploads/2023/02/cropped-CuraTeQ-Favicon-32x32.png Biologics Archives - CuraTeQ Biologics https://curateqbio.com/tag/biologics/ 32 32 CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India https://curateqbio.com/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india/ https://curateqbio.com/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india/#respond Wed, 17 Jan 2024 10:08:50 +0000 https://curateqbio.com/?p=2505 The post CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India appeared first on CuraTeQ Biologics.

]]>

Aurobindo Pharma Ltd’s wholly-owned subsidiary, CuraTeQ Biologics Private Ltd, on Wednesday, January 17, received marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for biosimilar trastuzumab.

In a stock exchange filing, Aurobindo Pharma said that CuraTeQ Biologics received a recommendation for grant of marketing authorisation of biosimilar trastuzumab from the Subject Experts Committee (SEC) of CDSCO, the apex drug regulator in India.

Trastuzumab biosimilar is a humanised monoclonal antibody that is used in the treatment of metastatic breast cancer and early breast cancer.

This monoclonal antibody is supplied in single dose glass vials that contain lyophilized powder in the dosages of 150 mg and 420 mg as concentrate for solution for infusion, Aurobindo Pharma informed the bourses.
CuraTeQ was asked to submit Phase IV clinical trial protocol to CDSCO within three months of receiving the marketing authorisation.

Article excerpt reposted from cnbctv18.com

The post CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India appeared first on CuraTeQ Biologics.

]]> https://curateqbio.com/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india/feed/ 0 CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector https://curateqbio.com/curateq-biologics-enters-into-global-biologics-cdmo-space/ https://curateqbio.com/curateq-biologics-enters-into-global-biologics-cdmo-space/#respond Mon, 20 Nov 2023 05:42:37 +0000 https://curateqbio.com/?p=2442 The post CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector appeared first on CuraTeQ Biologics.

]]>

Aurobindo Pharma Ltd’s wholly-owned subsidiary, CuraTeQ Biologics Private Ltd, on Wednesday, January 17, received marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for biosimilar trastuzumab.

In a stock exchange filing, Aurobindo Pharma said that CuraTeQ Biologics received a recommendation for grant of marketing authorisation of biosimilar trastuzumab from the Subject Experts Committee (SEC) of CDSCO, the apex drug regulator in India.

Trastuzumab biosimilar is a humanised monoclonal antibody that is used in the treatment of metastatic breast cancer and early breast cancer.

This monoclonal antibody is supplied in single dose glass vials that contain lyophilized powder in the dosages of 150 mg and 420 mg as concentrate for solution for infusion, Aurobindo Pharma informed the bourses.
CuraTeQ was asked to submit Phase IV clinical trial protocol to CDSCO within three months of receiving the marketing authorisation.

Article excerpt reposted from cnbctv18.com

The post CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector appeared first on CuraTeQ Biologics.

]]> https://curateqbio.com/curateq-biologics-enters-into-global-biologics-cdmo-space/feed/ 0